Moderna Sees COVID-19 Vaccine Surplus By 2022 If Constraints Ease
US Asked To Lift DPA Restrictions
Executive Summary
Moderna, GSK and Bharat Biotech point to technology transfer, material shortages and manufacturing expertise as factors constraining COVID-19 vaccine supplies, rather than intellectual property rights. Meanwhile, Moderna's CEO forecasts a surplus of these vaccines by 2022.
You may also be interested in...
MPP’s Guide To Cutting Biosimilar Approval Times, Costs By Third Or More
The Medicines Patent Pool has conducted a study on the impact of licensing and technology transfer on the timeline and costs of developing five biosimilars, including Merck’s Keytruda. While a licensing deal for pembrolizumab might not be a near-term possibility, the findings could help licensors, licensees and regulators increase access to medicines.
MPP's Guide To Cutting Biosimilar Approval Times, Costs By Third Or More
The Medicines Patent Pool has conducted a study on the impact of licensing and technology transfer on the timeline and costs of developing five biosimilars, including Merck’s Keytruda. While a licensing deal for pembrolizumab might not be a near-term possibility, the findings could help licensors, licensees and regulators increase access to medicines.
Biological E's COVID-19 Vaccine Launched, MD Says India Supplies To WHO Not Under Threat
Despite Indian companies not being able to honor COVID-19 vaccine export commitments, Biological E’s MD believes mitigating circumstances mean relations with the agency won’t be damaged. Meanwhile, Corbevax is being used in India's immunization program and a tech transfer for Johnson & Johnson’s COVID-19 vaccine is going ahead.